CELZ · Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc. (CELZ) reported Q1 FY2026 results reflecting continued investment in its clinical pipeline without revenue generation. Revenue fell to $0 from $3K in the prior-year quarter, a -100% decline, as the Company remains in its development phase with emphasis on advancing novel therapeutic cell lines including the AlloStemSpine® Chronic Lower Back Pain (CELZ-201 ADAPT) trial.

Operating income improved to -$1,459,153 from -$1,660,478 year-over-year, a 12.1% reduction in loss magnitude. This narrowing reflects cost discipline in a capital-intensive biotech environment. Management's discussion highlights that operating activities consumed cash primarily due to these losses, yet the Company maintained focus on core R&D efforts offset by general development efficiencies.

Net income followed suit, improving to -$1,405,077 from -$1,638,097, or 14.2% better, driven by the same operational dynamics. Diluted EPS was -$0.38 versus $0.83 prior year, with the shift to loss reflecting the absence of prior profitability amid heightened development spend, though losses are contracting.